The U.S. Food and Drug Administration (FDA) recently approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALZENNA is the first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with this condition. The FDA’s approval of the combination […]
The Jackson, Mississippi Prostate Cancer Disparity Rally mobilized leaders to record prostate cancer awareness messages.
PHENPath.com – Empowering Patients
PHEN Supports Talapro-3 Clinical Trial
The FDA approves a new prostate cancer combination treatment based upon a successful clinical trial
If you are experiencing PSA recurrence after surgery, PHENPath.com provides information about available treatment options as set forth by NCCN Guidelines®©2020-2024 Prostate Health Education Network, Inc. All Rights Reserved.
Supported by:
